Ticker brief
KLRA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
2
crowd 14d
+1.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-15 · now +0.40 (−1 bearish … +1 bullish)
Who spoke2
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.87 | 4 | +0.41 |
| @Pharmdca | C | -3.41 | 1 | +0.50 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @bioinvestor24 | +0.40 | Predicts Lilly may develop a diabetes-product gap as emerging dual agonists outperform, while viewing Novo combinations poorly. | · | tweet ↗ |
| 2026-10-09 | @bioinvestor24 | +0.75 | Favors injectable obesity therapies over pills and calls both KLRA and VKTX undervalued. | · | tweet ↗ |
| 2026-10-09 | @bioinvestor24 | +0.25 | Uses published agonism data to favor Lilly's GIP approach and criticize glucagon and AbbVie's amylin strategy. | · | tweet ↗ |
| 2026-10-07 | @Pharmdca | +0.50 | Expects obesity-sector interest to revive because the opportunity and strategic value remain large. | · | tweet ↗ |
| 2026-10-06 | @bioinvestor24 | +0.25 | Says KLRA is the only serious Chinese effort so far, though progress took a long time. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.